Takeda Hits Back At Stada's ADHD Drug IP Challenge
Takeda has defended the validity of its extended patent protections for ADHD drug Elvanse, asking a London court to reject Stada's attempt to quash a U.K. supplementary protection certificate, or SPC,...To view the full article, register now.
Already a subscriber? Click here to view full article